And you probably find some 1,000 pre-cash flow positive bio-techs listed globally, and many more outside the sector, with the same standardised 'going concern' caveat in the audited accounts.
Why this required a separate thread for a standard auditing caveat defeats me. A normally intelligent poster, if a little bombastic at times.
The company has stated its expectated cash runway so many times now, and we normally have the down-rampers ignorantly clouding the guidance, now even long-term holders doing the same! How many times do the CEO and Chair have to reiterate the slow down in spend:
"In accordance with ASX rules, the “Estimated quarters of funding available” reported in item 8.5 of the Appendix 4C is calculated by dividing the cash at the end of the quarter by the net operating cash outflows in the previous quarter, and the result of this calculation is 2.2 quarters of funding available. However, as the net operating cash outflows in the previous quarter were not representative of forecasted expenditure in the year ahead, this is not consistent with the Company’s expectations. The Company currently expects its cash runway to extend into the 2025-26 financial year. In item 6 of the Appendix 4C cash flow report for the quarter, payments to related part." (my embolden).
CYP Price at posting:
19.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)